Pulse Biosciences is a medical device company developing ablation technologies using its proprietary Nanosecond Pulsed Field Ablation (nsPFA) energy. The company’s core platform, the nPulse System, delivers nanosecond-duration electrical pulses to nonthermally clear targeted cells while sparing adjacent noncellular tissue. Its primary commercial product is the Vybrance Percutaneous Electrode System, a disposable needle electrode used with the nPulse Console for the ablation of soft tissue, including benign thyroid nodules, in percutaneous and intraoperative surgical procedures. The company is also advancing cardiac applications for the treatment of atrial fibrillation, including a surgical ablation clamp and an endocardial ablation catheter. Pulse Biosciences holds a global patent portfolio of over 130 issued patents and has received FDA 510(k) clearance for its percutaneous electrode system and Breakthrough Device Designation for its cardiac surgery system. The company serves healthcare providers and patients in the United States and internationally, with clinical trials and commercial pilots conducted in the U.S. and Italy.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage pulsebiosciences.com
Sector Healthcare IR page investors.pulsebiosciences.com
Tags
ablation, nanosecond pulsed field ablation, atrial fibrillation, thyroid nodule treatment, cardiac surgery, electrophysiology, soft tissue ablation, medical devices, nPulse System, Vybrance Percutaneous Electrode System, nPulse Console, nPulse Cardiac Surgical Clamp, nPulse Cardiac Catheter System, CellFX
Press page —

Metrics

Valuation  
Market cap $ 3.66B
Market cap (USD) $ 3.66B
P/E -41.26
PEG —
P/BV 19.94
P/S —
P/OCF -57.79
P/FCF -57.45
Dividend yield —
Turnover / mcap —
Returns  
ROE -74.4%
ROI -1,237.6%
ROIC -981.2%
Profit margin -20,794.6%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 56
Quality score -80.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015
Revenue 350K 0 0 700K 1.418M — — — — — —
Net profit -72.781M -53.585M -42.21M -58.505M -63.66M -49.851M -46.971M -37.545M -25.567M -9.518M -2.811M
Free cash flow -54.437M -36.468M -33.162M -47.414M -54.534M -35.806M -34.793M -24.172M -13.638M -8.115M -3.403M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015
Share price 13.73 17.41 12.24 2.77 14.81 23.86 13.41 11.46 23.6 6.49 —
Price performance 12m -0.21 0.42 3.42 -0.81 -0.38 0.78 0.17 -0.51 2.63 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — — 61,000 0.00 — 0.00 274,000
↳ YoY growth -100.0%
Lease liabilities (USD) — — — 6.72M 11.4M 10.8M 10M 9.14M 8.9M 7.53M
Cash and deposits (USD) 2.09M 3.39M 51.1M 6.9M 12.5M 28.6M 61.1M 44.4M 118M 80.7M
Intangible assets (USD) 6.54M 5.88M 5.21M 4.55M 3.88M 3.22M 2.55M 1.89M 1.22M 575,000
Right-of-use assets (USD) — — — 5.11M 9.44M 8.79M 8.06M 7.26M 7.16M 6.01M
Cash flow detail
Operating cash flow (USD) -8.05M -11.1M -23.9M -34.2M -35.4M -54.1M -47M -33M -36.3M -54.1M
Purchases of property, plant and equipment (USD) -64,000 -2.55M -276,000 -608,000 -441,000 -437,000 -401,000 -121,000 -125,000 -315,000
Purchases of intangible assets (USD) — — — — — — — — 0.00 -20,000
Change in receivables (cash effect) (USD) — — — — 0.00 -61,000 61,000 0.00 0.00 -274,000
Change in inventories (cash effect) (USD) — — — — 0.00 -5.82M -2.65M 0.00 0.00 -136,000
Change in payables (cash effect) (USD) 3,000 517,000 490,000 646,000 -266,000 1.16M -1.3M 263,000 -201,000 1.13M
Share-based compensation (USD) 870,000 10.9M 12.3M 11.3M 10.1M 14.6M 5.19M 7.18M 13.6M 21.5M
Operating cash flow before change in receivables (USD) — — — — -35.4M -54M -47.1M -33M -36.3M -53.8M
Free cash flow (OCF - PPE - intangibles) (USD) -8.12M -13.6M -24.2M -34.8M -35.8M -54.5M -47.4M -33.2M -36.5M -54.5M
Income detail
Research and development expense (USD) 5.99M 9.65M 17.3M 25M 26.4M 28.6M 20.8M 27.8M 32.3M 44.7M
↳ 5y CAGR +59.3% +36.8% +16.7% +10.0% +5.3% +11.1%
Total comprehensive income (USD) -9.53M -25.6M -37.5M -47M -49.9M -63.7M -58.5M -42.2M -53.6M -72.8M
Comprehensive income to owners (USD) -9.53M -25.6M -37.5M -47M -49.9M -63.7M -58.5M -42.2M -53.6M -72.8M
Reported Mar 20, 2017 Mar 16, 2018 Mar 14, 2019 Mar 16, 2020 Mar 31, 2023 Mar 31, 2022 Mar 31, 2023 Mar 28, 2024 Feb 19, 2026 Feb 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

86% of patients evaluated achieved at least 50% nodule volume reduction at six months after a single nonthermal nsPFA treatment, with significant improvements in symptoms and quality of life and no serious adverse events

HAYWARD, Calif.--(BUSINESS WIRE)--Nov. 6, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced interim six-month results from PRECISE-BTN, a prospective, multicenter U.S. study evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for the treatment of symptomatic and hyperfunctioning benign thyroid nodules (BTNs). The results were presented at the 95th Annual Meeting of the American Thyroid Association (ATA), held November 4–7, 2026, in Philadelphia.

For this interim dataset, 43 patients treated at three U.S. centers had reached the six-month assessment for the study's primary endpoint. Key findings include:

  • Nodule volume reduction: 86% of patients achieved the primary endpoint of at least 50% nodule volume reduction at six months. Median volume reduction was 72% at six months, with the majority of reduction evident by the one-month visit and continuing to improve over time.

  • Quality of life and symptomatic relief: The ThyPRO-39 Overall Quality of Life Impact score improved by 78% from baseline at six months. Among patients who reported neck pressure or fullness at baseline, the symptom had fully resolved in 82% of patients at six months.

  • Safety: No serious adverse events were reported.

"These six-month results are encouraging," said Ralph Tufano, MD, Director of the Multidisciplinary Thyroid and Parathyroid Center at Sarasota Memorial Hospital and principal investigator of the PRECISE-BTN study, who presented the data at ATA. "Volume reduction was apparent within the first month and continued through six months, and most patients experienced meaningful improvement in symptoms and quality of life. For patients with hyperfunctioning nodules, it is meaningful to see thyroid hormone levels improve while thyroid function is preserved. We look forward to the 12-month results."

"It is exciting to see these results across both symptomatic and hyperfunctioning nodules, with the safety profile available with nsPFA treatment," said Thomas Fahey, MD, investigator at Weill Cornell Medicine. "A nonthermal, ultrasound-guided option that is safe around the nerves and surrounding critical structures is becoming a meaningful addition for appropriately selected patients."

"Many patients come to us asking for a way to treat their nodules without surgery," said Kepal Patel, MD, investigator at NYU Langone Health. "What they want is relief from their symptoms without putting thyroid function at risk, and these interim results are encouraging on both counts.”

The nPulse Vybrance Percutaneous Electrode System delivers ultra-short bursts of electrical energy to cells in a precise nonthermal procedure under ultrasound guidance. Unlike treatments that rely on heat, nsPFA energy is designed to clear ablated cells while sparing adjacent acellular tissue to preserve nearby critical structures such as nerves and vessels. Patients undergoing treatment with the Vybrance System are able to go home the same day, avoid surgical risks and scarring, and typically experience relief from symptoms commencing only a few weeks following the minimally invasive procedure.

"PRECISE-BTN was designed to evaluate whether the results of our early feasibility work could be reproduced in a rigorous, prospective multicenter setting, and these six-month interim data are an encouraging step toward that goal," said Paul LaViolette, CEO and Co-Chairman of Pulse Biosciences. "We are particularly encouraged by the safety profile to date and by the results in both symptomatic and hyperfunctioning nodules. We thank our investigators, clinical sites, and study participants, and we look forward to reporting full results once all patients have completed 6-month follow-up."

Follow-up in the PRECISE-BTN study is ongoing, and the Company expects to report data for all patients in the Study at six months, the study's primary endpoint, and at 12 months as follow-up is completed.

About the PRECISE-BTN Study

The PRECISE-BTN study is a prospective, single-arm, multicenter clinical investigation designed to evaluate the safety and effectiveness of the nPulse™ Vybrance™ Percutaneous Electrode System using nsPFA energy for the treatment of symptomatic benign thyroid nodules. The study completed 100 patient enrollment at three U.S. centers, including principal investigator Ralph Tufano, MD, of Sarasota Memorial Health Care System in Sarasota, Florida, investigator Kepal Patel, MD, of NYU Langone Health in New York, and investigators Thomas Fahey, MD, and Brendan Finnerty, MD, of Weill Cornell Medicine. Patients are followed at 1, 3, 6, and 12 months post-procedure. The primary endpoint is nodule volume reduction of at least 50% at six months; additional endpoints include safety, symptomatic relief, hormone normalization, and improvements in quality of life.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company’s proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.

Pulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements concerning early clinical successes and whether they are predictive of the safety and effectiveness of any medical device such as the nPulse™ Vybrance™ Percutaneous Electrode System to treat benign thyroid nodules or any other thyroid disease, Pulse Biosciences’ expectations, whether stated or implied, about whether the Company’s nsPFA technology will become either a disruptive treatment option or a superior option for treating any medical condition such as thyroid disease, statements relating to the effectiveness of the Company’s nsPFA technology and nPulse System to non-thermally clear cells while sparing adjacent non-cellular tissue, statements concerning the Company’s expected clinical initiatives and product development efforts, such as expectations that the Company’s early feasibility work in the treatment of BTNs can be reproduced in a rigorous, prospective, multicenter clinical trial, customer adoption and future use of the nPulse System to address a range of conditions such as thyroid disease, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261106778880/en/

Investors: Pulse Biosciences, Inc. Jon Skinner, CFO [email protected]

Or

Gilmartin Group Philip Trip Taylor 415.937.5406 [email protected]

Source: Pulse Biosciences, Inc.

View all fonts in this project

Completed enrollment of NANOPULSE-AF US IDE pivotal study for treatment of AF with nPulse Cardiac Catheter System

Ended the quarter with $189 million of cash, cash equivalents, and marketable securities

HAYWARD, Calif.--(BUSINESS WIRE)--Nov. 5, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced business updates and financial results for the third quarter ended September 30, 2026.

“Pulse Biosciences delivered several major milestones since the second quarter, led by completing enrollment in our U.S. pivotal IDE study in just six months, three months ahead of plan,” said Paul LaViolette, CEO and Co Chairman of Pulse Biosciences. “That speed reflects the growing enthusiasm physicians have shown for the nPulse catheter since their very first cases. We also meaningfully strengthened our balance sheet, represented by institutional investor conviction in the opportunities ahead enabled by our technology and our team. With NANOPULSE-AF fully enrolled, and the capital to execute, we are now focused on preparations for launch readiness, additional data readouts, and regulatory submissions. We are also advancing new clinical study initiatives and exciting product development innovations, reflecting the deep application pipeline for our platform technology that gives us the opportunity to bring nsPFA to very large, underserved patient populations.”

Recent Business Highlights

  • Cash, cash equivalents, and marketable securities totaled $189.2 million as of September 30, 2026, compared to $101.6 million as of June 30, 2026. Based on current yields on cash, cash equivalents, and marketable securities at the current balance, provides over $7.5 million in annual interest income.

  • The Company raised $95.8 million in net proceeds through its ATM programs during the third quarter, and more than $150 million since May representing less than 6% dilution.

Endocardial Catheter AF Ablation

  • Completed enrollment in NANOPULSE-AF, the U.S. IDE pivotal study of the nPulse Cardiac Catheter System for the treatment of atrial fibrillation (AF), with 169 evaluable patients at 15 sites with 36 investigators. Enrollment was completed in under six months, three months faster than the timeline originally communicated.

  • Plans to present 12-month follow up data on 100 patients from the EU feasibility study in Q1 2027.

  • Continued to progress toward a CE Mark submission with anticipated CE mark approval in Q4 2027.

  • Plans to submit an IDE application for a persistent AF study in the fourth quarter of 2026, extending the nPulse catheter platform to larger and more complex patient groups.

Surgical AF Ablation and Soft Tissue Ablation

  • Continued to enroll NANOCLAMP-AF, the U.S. IDE pivotal study for concomitant surgical AF ablation, which remains on track to complete enrollment by the end of the first half of 2027. First patient enrolled in the trial has reached one year follow-up.

  • Recorded $0.4 million of third quarter revenue from Vybrance, compared to $0.1 million in the prior year period, while commercial case volume increased from prior quarters and important market development milestones were achieved focusing on existing account development.

  • Completed enrollment of the PRECISE-Benign Thyroid Nodule (PRECISE-BTN) study in September with 100 patients. Preliminary data are being presented at the American Thyroid Association annual meeting, with further data readouts expected after all patients achieve six-month and twelve-month follow-up.

Third Quarter 2026 Financial Results

Total revenue for the three months ended September 30, 2026 was $0.4 million, compared to $0.1 million in the prior year period. The Company remains in a controlled commercial launch of its Vybrance system, directing efforts toward market development and clinical use within a limited customer base. Results continue to be encouraging, we expect this phase of the Vybrance controlled launch to continue into Q4 2027.

Total GAAP costs and expenses, representing cost of product revenue, research and development, and selling, general and administrative expenses, for the three months ended September 30, 2026, were $24.7 million, an increase of $4.2 million compared to $20.5 million in the prior year period. The increase was primarily driven by increased investment in clinical program and employee-related spend. Non-GAAP costs and expenses for the three months ended September 30, 2026, were $19.1 million, an increase of $4.5 million compared to $14.6 million in the prior year period, driven by increased clinical program and employee-related spend.

GAAP net loss for the three months ended September 30, 2026 was ($23.1) million compared to ($19.4) million for the three months ended September 30, 2025. Non-GAAP net loss for the three months ended September 30, 2026, was ($17.5) million compared to ($13.5) million for the three months ended September 30, 2025.

Cash, cash equivalents, and marketable securities totaled $189.2 million as of September 30, 2026, compared to $101.6 million in cash and cash equivalents as of June 30, 2026. The sequential increase of $87.6 million reflects net proceeds raised under the Company’s ATM programs. Cash used in operating activities in the third quarter of 2026 totaled $15.3 million, compared to $13.0 million in the same period of the prior year and $18.7 million in the second quarter of 2026.

The Company raised $95.8 million in net proceeds through its ATM programs during the third quarter, bringing the total since May to more than $150 million, representing under 6% dilution. Approximately $64 million of ATM capacity remains available.

Reconciliations of GAAP to Non-GAAP costs and expenses and net loss have been provided in the tables following the financial statements in this press release. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures.”

Webcast and Conference Call Information

Pulse Biosciences’ management will host a conference call Thursday, November 5, 2026, beginning at 1:30pm PT. Investors interested in listening to the conference call may do so by dialing 1-800-715-9871 from the U.S. or 1-646-307-1963 internationally and providing Conference ID 9464498. A live and recorded webcast of the event will be available at https://investors.pulsebiosciences.com/.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company’s proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.

Pulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Non-GAAP Financial Measures

In this press release, in order to supplement the Company’s condensed consolidated financial statements presented in accordance with Generally Accepted Accounting Principles, or GAAP, management has disclosed certain non-GAAP financial measures for the statement of operations. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results in order to supplement investors’ and other readers’ understanding and assessment of the Company’s financial performance. Company management uses these measurements as aids in monitoring the Company’s ongoing financial performance from quarter to quarter, and year to year, on a regular basis and for financial and operational decision-making. Non-GAAP adjustments include stock-based compensation, depreciation and amortization, and a legal settlement. From time to time in the future, there may be other items that the Company may exclude if the Company believes that doing so is consistent with the goal of providing useful information to management and investors. The Company has provided a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure. Investors are cautioned that there are a number of limitations associated with the use of non-GAAP financial measures as analytical tools. Investors are encouraged to review these reconciliations, and not to rely on any single financial measure to evaluate the Company’s business.

Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies, which could reduce the usefulness of the Company’s non-GAAP financial measures as tools for comparison. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP. Non-GAAP financial measures in this earnings release exclude non-cash expenses for stock-based compensation, depreciation and amortization and legal settlement expenses.

Glossary of Terms

  • Arrhythmia: Any abnormal heart rhythm where the heart beats too fast, too slow, or irregularly due to electrical disturbances.

  • Atrial arrhythmia: Any abnormal heart rhythm originating in the atria, including AF, atrial flutter, and atrial tachycardia.

  • Atrial fibrillation (AF): Irregular, often rapid heartbeat starting in the atria that can cause symptoms and increase stroke risk.

  • Atrial tachycardia (AT): A rapid abnormal heart rhythm caused by electrical activity originating in the atria outside the heart’s normal pacemaker (sinus node).

  • Cavo tricuspid Isthmus (CTI): A region of right atrial tissue between the inferior vena cava and tricuspid valve that forms part of the electrical circuit in typical atrial flutter.

  • Electroanatomic mapping: 3D mapping of heart chambers that combines anatomy and electrical data to guide ablation.

  • Electrophysiology (EP): Cardiology subspecialty focused on the heart’s electrical system and the diagnosis and treatment of arrhythmias.

  • Myocardial Infarction (MI): Death of heart muscle tissue due to prolonged inadequate blood flow and oxygen supply, commonly called a heart attack.

  • Paroxysmal atrial fibrillation: AF episodes that start and stop on their own, typically lasting less than seven days.

  • Persistent Atrial Fibrillation: Continuous AF lasting more than seven days.

  • Pulsed Field Ablation (PFA): Non‑thermal ablation using short, high‑voltage pulses to selectively injure cardiac cells via irreversible electroporation.

  • Posterior Wall Isolation (PWI): Ablation technique that electrically isolates the posterior wall of the left atrium to target electrical activity that may initiate or sustain AT or AF.

  • Premature ventricular contraction (PVC): An early heartbeat originating in the ventricles that interrupts the normal heart rhythm and may feel like a skipped beat.

  • Pulmonary vein isolation (PVI): Ablation technique that electrically isolates the pulmonary veins from the left atrium to prevent AF triggers.

  • Ventricular Tachycardia (VT): A rapid abnormal heart rhythm originating in the ventricles that can impair blood flow and may be life-threatening.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements concerning early clinical successes and whether they are predictive of the safety and effectiveness of any medical device such as the nPulse Cardiac Catheter System, statements concerning the anticipated timing of enrollment completion and possible outcomes in any of the Company’s clinical trials, statements concerning any of the Company’s regulatory submissions, including CE Mark submissions, FDA submissions, the planned IDE application for persistent AF and the potential regulatory approval of any Company product, Pulse Biosciences’ expectations, whether stated or implied, about whether the Company’s nsPFA technology will become either a disruptive treatment option or a superior option for treating atrial fibrillation or any other medical condition, statements relating to the effectiveness of the Company’s nsPFA technology and nPulse System to non-thermally clear cells while sparing adjacent non-cellular tissue, statements concerning the Company’s expected product development efforts, such as advancement of its nPulse Cardiac Catheter to treat atrial fibrillation, statements concerning market development and market opportunities, customer adoption and future commercialization of any nPulse product, such as the Vybrance Percutaneous Electrode System, statements concerning the Company’s partnership, manufacturing and financing activities, including its expected cash runway and available capacity under its ATM programs, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

| PULSE BIOSCIENCES, INC. |

| Condensed Consolidated Balance Sheets |

| (In thousands, except share and per share data) |

| (Unaudited) |

| | | | | | | |

| | | September 30, | | | December 31, | |

| | | 2026 | | | 2025 | |

| ASSETS | | | | | | | | |

| Current assets: | | | | | | | | |

| Cash and cash equivalents | | $ | 36,725 | | | $ | 80,735 | |

| Marketable securities | | | 152,469 | | | | — | |

| Accounts receivable | | | 297 | | | | 274 | |

| Inventory | | | 232 | | | | 136 | |

| Prepaid expenses and other current assets | | | 2,485 | | | | 2,276 | |

| Total current assets | | | 192,208 | | | | 83,421 | |

| | | | | | | | | |

| Property and equipment, net | | | 1,073 | | | | 1,051 | |

| Intangible assets, net | | | 55 | | | | 575 | |

| Goodwill | | | 2,791 | | | | 2,791 | |

| Right-of-use assets | | | 5,059 | | | | 6,010 | |

| Other assets | | | 398 | | | | 691 | |

| Total assets | | $ | 201,584 | | | $ | 94,539 | |

| | | | | | | | | |

| LIABILITIES AND STOCKHOLDERS’ EQUITY | | | | | | | | |

| Current liabilities: | | | | | | | | |

| Accounts payable | | $ | 3,018 | | | $ | 2,777 | |

| Accrued liabilities | | | 8,630 | | | | 3,576 | |

| Lease liability, current | | | 1,747 | | | | 1,570 | |

| Total current liabilities | | | 13,395 | | | | 7,923 | |

| | | | | | | | | |

| Lease liability, less current portion | | | 4,616 | | | | 5,960 | |

| Total liabilities | | | 18,011 | | | | 13,883 | |

| | | | | | | | | |

| Stockholders’ equity: | | | | | | | | |

| Preferred stock, $0.001 par value; authorized – 50,000,000 shares; no shares issued and outstanding | | | — | | | | — | |

| Common stock, $0.001 par value; authorized – 500,000,000 shares; issued and outstanding – 73,314,797 shares and 67,839,689 shares as of September 30, 2026 and December 31, 2025, respectively | | | 73 | | | | 68 | |

| Additional paid-in capital | | | 713,153 | | | | 543,869 | |

| Accumulated other comprehensive loss | | | (83 | ) | | | — | |

| Accumulated deficit | | | (529,570 | ) | | | (463,281 | ) |

| Total stockholders’ equity | | | 183,573 | | | | 80,656 | |

| Total liabilities and stockholders’ equity | | $ | 201,584 | | | $ | 94,539 | |

| PULSE BIOSCIENCES, INC. |

| Condensed Consolidated Statements of Operations |

| (In thousands, except share and per share data) |

| (Unaudited) |

| | | | | | | |

| | | Three Months Ended | | | Nine Months Ended | |

| | | September 30, | | | September 30, | |

| | | 2026 | | | 2025 | | | 2026 | | | 2025 | |

| Revenue: | | | | | | | | | | | | | | | | |

| Product revenue | | $ | 395 | | | $ | 86 | | | $ | 1,230 | | | $ | 86 | |

| | | | | | | | | | | | | | | | | |

| Cost and expenses: | | | | | | | | | | | | | | | | |

| Cost of product revenue | | | 191 | | | | 279 | | | | 834 | | | | 279 | |

| Research and development | | | 16,848 | | | | 11,393 | | | | 46,414 | | | | 33,794 | |

| Selling, general and administrative | | | 7,648 | | | | 8,781 | | | | 22,696 | | | | 24,699 | |

| Total cost and expenses | | | 24,687 | | | | 20,453 | | | | 69,944 | | | | 58,772 | |

| Loss from operations | | | (24,292 | ) | | | (20,367 | ) | | | (68,714 | ) | | | (58,686 | ) |

| | | | | | | | | | | | | | | | | |

| Other income (expense): | | | | | | | | | | | | | | | | |

| Interest income | | | 1,205 | | | | 1,001 | | | | 2,398 | | | | 3,385 | |

| Other income (expense) | | | 36 | | | | (19 | ) | | | 27 | | | | (47 | ) |

| Total other income | | | 1,241 | | | | 982 | | | | 2,425 | | | | 3,338 | |

| Net loss | | $ | (23,051 | ) | | $ | (19,385 | ) | | $ | (66,289 | ) | | $ | (55,348 | ) |

| | | | | | | | | | | | | | | | | |

| Net loss per share, basic and diluted | | $ | (0.32 | ) | | $ | (0.29 | ) | | $ | (0.95 | ) | | $ | (0.82 | ) |

| Weighted average common shares outstanding, basic and diluted | | | 71,929,228 | | | | 67,385,281 | | | | 69,722,351 | | | | 67,263,426 | |

| |

| | | Three Months Ended | | | Nine Months Ended | |

| | | September 30, | | | September 30, | |

| Stock Based Compensation Expense: | | 2026 | | | 2025 | | | 2026 | | | 2025 | |

| Cost of product revenue | | $ | 20 | | | $ | 52 | | | $ | 92 | | | $ | 52 | |

| Research and development | | | 2,275 | | | | 2,232 | | | | 6,560 | | | | 7,329 | |

| Selling, general and administrative | | | 3,017 | | | | 3,333 | | | | 5,545 | | | | 9,106 | |

| Total stock-based compensation expense | | $ | 5,312 | | | $ | 5,617 | | | $ | 12,197 | | | $ | 16,487 | |

| Reconciliation of GAAP to Non-GAAP Financial Measures |

| The following table presents the reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures: |

| (In thousands) |

| (Unaudited) |

| | | | | | | |

| | | Three Months Ended | | | Nine Months Ended | |

| | | September 30, | | | September 30, | |

| | | 2026 | | | 2025 | | | 2026 | | | 2025 | |

| Reconciliation of GAAP to non-GAAP Cost of product revenue: | | | | | | | | | | | | | | | | |

| GAAP Cost of product revenue | | $ | 191 | | | $ | 279 | | | $ | 834 | | | $ | 279 | |

| Stock-based compensation expense | | | (20 | ) | | | (52 | ) | | | (92 | ) | | | (52 | ) |

| Depreciation and amortization | | | — | | | | (3 | ) | | | — | | | | (3 | ) |

| Non-GAAP Cost of product revenue | | $ | 171 | | | $ | 224 | | | $ | 742 | | | $ | 224 | |

| | | | | | | | | | | | | | | | | |

| Reconciliation of GAAP to non-GAAP Research and development: | | | | | | | | | | | | | | | | |

| GAAP Research and development | | $ | 16,848 | | | $ | 11,393 | | | $ | 46,414 | | | $ | 33,794 | |

| Stock-based compensation expense | | | (2,275 | ) | | | (2,232 | ) | | | (6,560 | ) | | | (7,329 | ) |

| Depreciation and amortization | | | (48 | ) | | | (41 | ) | | | (134 | ) | | | (131 | ) |

| Non-GAAP Research and development | | $ | 14,525 | | | $ | 9,120 | | | $ | 39,720 | | | $ | 26,334 | |

| | | | | | | | | | | | | | | | | |

| Reconciliation of GAAP to non-GAAP Selling, general and administrative: | | | | | |

| GAAP Selling, general and administrative | | $ | 7,648 | | | $ | 8,781 | | | $ | 22,696 | | | $ | 24,699 | |

| Stock-based compensation expense | | | (3,017 | ) | | | (3,333 | ) | | | (5,545 | ) | | | (9,106 | ) |

| Depreciation and amortization | | | (213 | ) | | | (212 | ) | | | (636 | ) | | | (678 | ) |

| Legal settlement | | | — | | | | — | | | | — | | | | 590 | |

| Non-GAAP Selling, general and administrative | | $ | 4,418 | | | $ | 5,236 | | | $ | 16,515 | | | $ | 15,505 | |

| | | | | | | | | | | | | | | | | |

| Reconciliation of GAAP to non-GAAP Cost and expenses: | | | | | | | | | | | | | | | | |

| GAAP Cost and expenses | | $ | 24,687 | | | $ | 20,453 | | | $ | 69,944 | | | $ | 58,772 | |

| Stock-based compensation expense | | | (5,312 | ) | | | (5,617 | ) | | | (12,197 | ) | | | (16,487 | ) |

| Depreciation and amortization | | | (261 | ) | | | (256 | ) | | | (770 | ) | | | (812 | ) |

| Legal settlement | | | — | | | | — | | | | — | | | | 590 | |

| Non-GAAP Cost and expenses | | $ | 19,114 | | | $ | 14,580 | | | $ | 56,977 | | | $ | 42,063 | |

| | | | | | | | | | | | | | | | | |

| Reconciliation of GAAP to non-GAAP Net loss: | | | | | | | | | | | | | | | | |

| GAAP Net loss | | $ | (23,051 | ) | | $ | (19,385 | ) | | $ | (66,289 | ) | | $ | (55,348 | ) |

| Stock-based compensation expense | | | 5,312 | | | | 5,617 | | | | 12,197 | | | | 16,487 | |

| Depreciation and amortization | | | 261 | | | | 256 | | | | 770 | | | | 812 | |

| Legal settlement | | | — | | | | — | | | | — | | | | (590 | ) |

| Non-GAAP Net loss | | $ | (17,478 | ) | | $ | (13,512 | ) | | $ | (53,322 | ) | | $ | (38,639 | ) |

View source version on businesswire.com: https://www.businesswire.com/news/home/20261105622360/en/

Investors: Pulse Biosciences, Inc. Jon Skinner, CFO [email protected] Or Gilmartin Group Philip Trip Taylor 415.937.5406 [email protected]

Source: Pulse Biosciences, Inc.

View all fonts in this project

HAYWARD, Calif.--(BUSINESS WIRE)--Oct. 29, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans to participate in the upcoming Stifel 2026 Healthcare Conference in New York, NY.

Pulse Biosciences’ Management is scheduled to present on Thursday, November 12, at 11:20 am ET. A live and recorded webcast of the presentation will be available on the “Events Calendar and Presentations” page of the company’s investor website at http://investors.pulsebiosciences.com/.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company’s proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.

Pulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261029313341/en/

Investor Contact: Pulse Biosciences, Inc. Jon Skinner, CFO [email protected]

Or

Gilmartin Group Philip Trip Taylor 415.937.5406 [email protected]

Source: Pulse Biosciences, Inc.

View all fonts in this project

Prompts

Pulse Biosciences, Inc (ticker PLSE), listed in United States.

Company History

Date Change Detail
Dec 22, 2015 Renamed Electroblate, Inc. → PULSE BIOSCIENCES, INC.

ETFs Holding Pulse Biosciences, Inc

ETF Weight in ETF Shares Market value As of
ESSC 0.15% 1,567 $ 55.049K Jul 31, 2026
VFMO 0.15% 55,661 $ 2.801M Aug 31, 2026
MSSM 0.01% 759 $ 38.2K Aug 31, 2026